{"name":"Nichi-Iko Pharmaceutical Co., Ltd.","slug":"nichi-iko-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"NI-071","genericName":"NI-071","slug":"ni-071","indication":"Cognitive impairment associated with schizophrenia","status":"phase_3"}]}],"pipeline":[{"name":"NI-071","genericName":"NI-071","slug":"ni-071","phase":"phase_3","mechanism":"NI-071 is a selective inhibitor of phosphodiesterase 9 (PDE9) that increases cyclic GMP signaling in the central nervous system.","indications":["Cognitive impairment associated with schizophrenia"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxNdThSY3RXcDljeTJKSUVLenh4ZjlfekRVSUZIMVJQWDJNSDAxdWdNQ194NVFQNk9vd1FhMFJwbUxlOF9XRDlBTE1TZXpocmZPcVVQMEpsNUdkUEVOTG1QR0pWNkwyX1NRcXJyQUw3VF9sYWZHYzBEYWN6WmdWSVhFOFBGMW85WGJ1TU0wajhSdzJsOWZOZ2lJUUpfRE8zaFU2RHNMcjE0eFN2cENiV09NX09Wd3lTRXNvZmdoZG54bkhXLXF4RElrVi01aFpsYmFhWTFvNU5XQWFfZm1yWUw5aFNwbw?oc=5","date":"2026-02-07","type":"deal","source":"lupin.com","summary":"Lupin and Nichi-Iko announce strategic partnership for commercialization of biosimilar Etanercept in Japan - lupin.com","headline":"Lupin and Nichi-Iko announce strategic partnership for commercialization of biosimilar Etanercept in Japan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxOb2FEM0FkS1lYdkRGNWhCcDZCRFRrT1Y5Z3JGNndiYUhZcGFtZWwyV014QU9NbTFPcXVhN2poTFc3azNRZWJuaTVhN2JtLUE4YkVxQTR6U0NMQWswYXVRTlNuSnhGX245ZTZUb1RsTzlMN3VSdU5kY1praTQ3QWwyTHcxZ1Y1WGVpOFVOTzBpLWVneFhxSG82MG9JaW1XWXotUTE2ZTM2UFpaaFRkYy1CZ2EtMWE2Vk9QU3AzOWh6OTI?oc=5","date":"2023-08-08","type":"pipeline","source":"Latham & Watkins LLP","summary":"Latham Advises Nichi-Iko Pharmaceutical on Sale of Sagent Pharmaceuticals and Omega Laboratories - Latham & Watkins LLP","headline":"Latham Advises Nichi-Iko Pharmaceutical on Sale of Sagent Pharmaceuticals and Omega Laboratories - Latham & Watkins LLP","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNS2NMdmZuREJ1VkJiMEo4VVBaeWlub3FKS3haMDg2SmEyRTRuaXNSMDRRX3A4SHFuVHpDMFJINWVLYzFhRnFicXp4ZzZlb3VIcWNpY0xzOXJPZnNmWE82TjhjcFZpWWwyd1RyOHR3ZWFVUXlPX0RkdUJqMjI0UUM1VlgzU0Q1Qlp2ZFNZbFJ6TmktbGNEMTAwYUVJNTcyT00yR1R0QQ?oc=5","date":"2023-03-01","type":"pipeline","source":"Citeline News & Insights","summary":"Down But Not Out: Nichi-Iko Hives Off Sagent, Exits North America - Citeline News & Insights","headline":"Down But Not Out: Nichi-Iko Hives Off Sagent, Exits North America - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNZkg0ODdzX1gwR3RWTzFPN2VvbGwzeGwzZEdRbVNmMHY1eDgyemNvZi1aY0xJN0tIb296R2xRZ1RJZTh2ZUZNS1VXSURkN2dlbzAyLW94YUVHaC1fVTlOSERVYy03YlhxeTVDeXZvc0tjV0s1ODBJNXdCT0xUNThnTHhQSjc5WGZUakJsS2NmWmUtOXhE?oc=5","date":"2020-04-21","type":"pipeline","source":"openPR.com","summary":"Betahistine Market Rapidly Increasing In Size Globally - openPR.com","headline":"Betahistine Market Rapidly Increasing In Size Globally","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPUlNJM3VwbFJoa1BVZnVvVlNHeWsxX21WbWowZGRCVnh2MHR3bXFjSVRFX2YyUkhodmljU1VyY0ZMTGtYZzYwSU91RVVFNkpRVVk0SjhPVWktQjN4MFJUdTlKUXdyN2RwcWd1T2JmWDUzZ255NmRNOFhSWjlPRjE5MjZsSkpGdGpSRVVqOEJnMEx6UjExTDJjdV9zdGc2Sk1a?oc=5","date":"2019-11-11","type":"pipeline","source":"Citeline News & Insights","summary":"Lupin Offloads Kyowa Pharma For $525m But Not Exiting Japan - Citeline News & Insights","headline":"Lupin Offloads Kyowa Pharma For $525m But Not Exiting Japan - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxONnBkMGo4RzFfSzd5UlRyLVZOM1NQREUtd3o3MDQ3VW9XWUxHelV6dTF3aEJ1X0RDdVQ4NG96dG93TTZSWXpFV3RBb0haeS1RSENwdzZJdldsSlM5XzBWcHVaMGNqOEtFTGlNU000aThFLUlhODJoMkJRMVVNbkZ4UzlBS3psZEp3SlpRUWRyWnJwb2xyY3J1RTZrdFVUU0RtczNHSE1HaUxDNm5fYkNYQnI4QTJBang1STh6UGJwNzlTOGhEZDJ1MElNWQ?oc=5","date":"2019-09-05","type":"regulatory","source":"PR Newswire","summary":"Sagent Pharmaceuticals Announces FDA Acceptance of Omega Manufacturing Site - PR Newswire","headline":"Sagent Pharmaceuticals Announces FDA Acceptance of Omega Manufacturing Site","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxORlpkb2dQdE1fRjdiLUdhWTNMNFZFeWJDZGVjX2x0S0paM3hwdUQ5ZWd0a3Rwa3ByX2VlT3Jid2kwVzFPVHZhTVpoUlYwdFVqTGE2Zjk1OGxqNi1qcW9LZXFPNnY1Y0pqeDc3b2k0VnhudWZ0OTFrTTB1Vl9JUzVkWkh0TVN5bE4xYWpESnNELWhOdWJ5UTRsbm02bGhDellWSklXRTg1UGdLV3prYTEwUHNnWDV0N05UeEZ3MFpkUTRRN3ZfMUxwNUVB?oc=5","date":"2019-03-01","type":"pipeline","source":"PR Newswire","summary":"Sagent Pharmaceuticals Announces Acquisition of Raleigh Manufacturing Site - PR Newswire","headline":"Sagent Pharmaceuticals Announces Acquisition of Raleigh Manufacturing Site","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNdmlWZlZJcy04T3dvVUVITlRJVXN6OHR4Rzh5MWNXTnFfWlZCSzh3RG4zU2tramdrbXlsQVFodERMb1hvVjF1dXp3eFJmNGphWTFPMUFmd3p4LWVJclJqa0JaX19ZaFJWUmVwanpJSWtGeGx6b1ZoeEZpX0lQYUZKY2VNS3RrRjIxejNVMG5wOXVrTC1k?oc=5","date":"2016-07-13","type":"deal","source":"Contract Pharma","summary":"Nichi-Iko Pharma Buys Sagent for $736 Million - Contract Pharma","headline":"Nichi-Iko Pharma Buys Sagent for $736 Million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNWnhSeDM5T1E1UXhPMnlIc3dvQS1xNEliS0poUnVhd2hoSERaWFQ1QlkwaTNKN21RVUFpTzlNcXRHaGFrQzUyNVFGN2FqVTlJNzFIajVlV0c1dmJVaG52Q0pieEh2TjVGRzdQRWVVLTlZdHJSVkpOd0FRQi1TYjVSaGNIekV1dU5BeXNUNFdPcmVCRFUyUFd3eWc2a3hJWmEzZzJ1bnFGMzJNQUlVTHBhLURTeUc?oc=5","date":"2016-07-11","type":"deal","source":"Bloomberg.com","summary":"Nichi-Iko Pharmaceutical to Buy Sagent in $736 Million Cash Deal - Bloomberg.com","headline":"Nichi-Iko Pharmaceutical to Buy Sagent in $736 Million Cash Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNYlZwMEc2QW1IcUxRZ0RQVlMwS3lQUEpsalR3WHBqNEpVc1Itd2t3WUdvalExQ0RHbVhCeUJSYXBqZV9QTVNOZTd4N1czSVdZRVdWRjBNc3pyNnB5ZUpjTXNFajVlMThVTGV1WVhGclo4MHRwcWRESWNvMllhWkVhLVZabHNzLTRVTERDLS13?oc=5","date":"2016-07-11","type":"deal","source":"Genetic Engineering and Biotechnology News","summary":"Nichi-Iko to Acquire Sagent Pharmaceuticals for $736M - Genetic Engineering and Biotechnology News","headline":"Nichi-Iko to Acquire Sagent Pharmaceuticals for $736M","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}